Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This study is to determine the effectiveness and safety of WR 279,396, a topical cream for
the treatment of cutaneous leishmaniasis. This study is to be conducted with a placebo
control under double-blind conditions in a local population group in Tunisia where
leishmaniasis is endemic.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command